Bicycle Therapeutics

October marks Black History Month in the UK and Ireland. For our #TeamBicycle colleague Yasmin Kinobe MPH, the month provides an opportunity to reflect and reconnect with her family’s roots on the African continent. "My mother first stepped foot in the UK in her twenties with a scholarship to London School of Economics to study her master’s degree, and yet the odds were stacked against her as she came from humble beginnings. Having lost her mother at 3 years old and been brought up by extended relatives, it is in the UK she met my father in the 1980s who was also Ugandan but working and living in Nigeria as an expat. The rest was history as they married and had me and my sisters soon after. She maintained a career in social work for 30+ years and continues to give back to her community, opening a transit home for children in Uganda. "Growing up as Black British in London has been a rich experience, being surrounded by a melting pot of nationalities regardless of race. Within the Black community alone, we represent numerous countries from Africa and the Caribbean and have made great contributions to the Commonwealth. "This year, the theme of Black History Month is 'Reclaiming Narratives,' highlighting the part played by the Black community in British life and bringing untold histories to the forefront. Children across the nation are being educated on the Windrush generation of emigrants from Jamaica who were brought to the UK in the 1940s, and Mary Seacole who rivalled Florence Nightingale in her assistance to wounded military personnel during the Crimean war. These were things I was never taught in school, so the efforts made to recognise and build pride as well as awareness are truly admirable."

Today we announced first human imaging data for our Bicycle Radionuclide Conjugate® targeting MT1-MMP, a novel tumor antigen, and outlined our strategy to develop next-generation #radiopharmaceuticals. Read more here: https://bit.ly/3UlNAoe.

At #EANM24, we look forward to sharing preclinical and first human imaging data for our Bicycle® Radio Conjugate targeting MT1-MMP, a novel tumor antigen expressed in many types of #cancer. We’ll also host a webcast for investors to review the data and outline our #radiopharmaceuticals strategy. More info: https://bit.ly/3NsDrlJ.

A warm welcome to our #TeamBicycle September new hires who joined our Development, Commercial, Finance, Clinical, Regulatory, Research and CMC & Supply Chain teams! Learn more about our careers and culture: https://bit.ly/3TS7ZA8.

Congrats to our #TeamBicycle colleague Zafar Qadir on his promotion to Chief Legal Officer and General Counsel! Zaf has played a critical role in supporting our company’s growth, and we look forward to seeing him succeed in this elevated role.

This #WorldCancerResearchDay, we recognize those who are working tirelessly to drive progress in #cancerresearch toward health equity. We are proud to do our part to discover and develop innovative medicines using our Bicycle® technology platform, with the goal of making a difference for every person affected by #cancer.

It’s an honor to be awarded Investment of the Year by Business Weekly newspaper! We’re grateful to be recognized for our $555 million PIPE financing to advance our efforts to develop medicines that not only help people with #cancer live longer but also live well. Congrats to all the winners! Photo credit: Business Weekly newspaper

At #ESMO24, we are proud to present updated clinical data for our investigational #cancer therapies zelenectide pevedotin, BT5528 and BT7480. Read more here: https://bit.ly/3B7ffm3. 

Many thanks to Endpoints News Lei Lei Wu for covering our #ESMO24 abstracts and our ambitions for our lead investigational therapy for #bladder cancer. As our CEO Kevin Lee said, “The [antibody drug conjugate] field has been remarkable in what it’s achieved for patients, but we need to also realize that while these molecules have provided great advantages in terms of efficacy, there’s a lot to achieve in terms of tolerability profiles.” Read the full article: https://lnkd.in/dC6WmDhD. 

Hot off the press: Phase 1 dose escalation results for our investigational Bicycle® Toxin Conjugate BT5528 are now published in the Journal of Clinical Oncology: https://lnkd.in/dEUqJtS9. Our deepest thanks to the patients, physicians and clinical site staff who contributed to these data. We look forward to presenting updated data for BT5528 at #ESMO24 next week.